Evolution of high-level daptomycin resistance in Enterococcus faecium during daptomycin therapy is associated with limited mutations in the bacterial genome

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 8, 2013, Pages 1926-1928

  Kelesidis, Theodoros ^a   Tewhey, Ryan ^b,c   Humphries, Romney M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD UNIVERSITY   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cardiolipin synthetase; Hypercalcaemia; Whole genome sequencing

Indexed keywords

CASPOFUNGIN; CEFEPIME; CIPROFLOXACIN; DAPTOMYCIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL DRAIN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL GENOME; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; CANDIDA ALBICANS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EXPOSURE; DRUG SUBSTITUTION; ELECTIVE SURGERY; ENTEROCOCCUS FAECIUM; FEMALE; FEVER; FRAMESHIFT MUTATION; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOPARATHYROIDISM; KIDNEY FAILURE; LETTER; LEUKOCYTOSIS; MORBID OBESITY; NONSENSE MUTATION; PANCREAS TUMOR; PANCREATICODUODENECTOMY; REPEAT PROCEDURE; THYROID CARCINOMA; TOTAL PARENTERAL NUTRITION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

CARDIOLIPIN SYNTHETASE; HYPERCALCAEMIA; WHOLE-GENOME SEQUENCING;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECIUM; FEMALE; GENOME, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MUTATION; SEQUENCE ANALYSIS, DNA; SURGICAL WOUND INFECTION; THYROID NEOPLASMS;

EID: 84880763052     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt117     Document Type: Letter

References (11)

1. Kelesidis T, Humphries R, Uslan DZ et al. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011; 52: 228-34.
2. Kelesidis T, Humphries R, Uslan DZ et al. De novo daptomycin-nonsusceptible enterococcal infections. Emerg Infect Dis 2012; 18: 674-6.
3. Kelesidis T, Chow AL, Humphries R et al. Case-control study comparing de novo and daptomycin-exposed daptomycin-nonsusceptible Enterococcus infections. Antimicrob Agents Chemother 2012; 56: 2150-2.
4. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement: M100-S22. CLSI, Wayne, PA, USA, 2012.
6. Humphries RM, Kelesidis T, Tewhey R et al. Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012; 56: 6051-3.
7. Arias CA, Panesso D, McGrath DM et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011; 365: 892-900.
8. Palmer KL, Daniel A, Hardy C et al. Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother 2011; 55: 3345-56.
9. Fuchs PC, Barry AL, Brown SD. Daptomycin susceptibility tests: interpretive criteria, quality control and effect of calcium on in vitro tests. Diagn Microbiol Infect Dis 2000; 38: 51-8.
10. 2+ and albumin on these drugs. Antimicrob Agents Chemother 1991; 35: 1710-6.
11. Salama NN, Segal JH, Churchwell MD et al. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol 2009; 4: 1190-4.